Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158096 | 0.79 | HDAC4 (0.52) | HDAC4NOS1CYP11B1CYP11B2NPC1 | |
| SCHEMBL890214 | 0.79 | SMN1; SMN2 (0.47) | HDAC4NOS1SRCCDK2ZAP70 | |
| SCHEMBL4541985 | 0.78 | HDAC4 (0.40) | HDAC4NOS1SRCCDK2ZAP70 | |
| SCHEMBL1722963 | 0.78 | CDC7 (0.53) | HDAC4NOS1SRCCDK2ZAP70 | |
| SCHEMBL18725088 | 0.78 | HDAC4 (0.44) | HDAC4NOS1SRCCDK2ZAP70 | |
| SCHEMBL11516196 | 0.78 | HSD17B1 (0.49) | HDAC4NPC1RAB9ASMN1; SMN2KDR | |
| SCHEMBL10013485 | 0.78 | SMN1; SMN2 (0.46) | HDAC4NOS1SRCCDK2ZAP70 | |
| SCHEMBL2095938 | 0.76 | SMN1; SMN2 (0.51) | HDAC4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2090445 | 0.76 | APP (0.44) | HDAC4NOS1METNPC1RAB9A | |
| SCHEMBL533700 | 0.76 | SMN1; SMN2 (0.37) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| CN-103965099-A | Pyridylaminoacetic Acid Compound | UBE INDUSTRIES | 2014-08-06 | — | — | CN | claimed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | claimed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | claimed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | claimed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | claimed |
| CN-102548985-A | Substituted carbonyl compounds | UBE INDUSTRIES | 2012-07-04 | — | — | CN | claimed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | claimed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | claimed |
| CN-101970410-A | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2011-02-09 | — | — | CN | claimed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | claimed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-12 | — | — | US | disclosed |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-06-21 | — | — | US | disclosed |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| EP-1482924-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-05-21 | — | — | EP | disclosed |
| US-7375134-B2 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | AXYS PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472360-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | HDAC4 4418/4885NOS1 4071/4885SRC 1303/4885 |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | HDAC4 1172/4885NOS1 1173/4885SRC 4429/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | HDAC4 1636/4885NOS1 1810/4885SRC 3910/4885 |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | CTSE, CTSL, CTSK | HDAC4 2594/4885NOS1 588/4885SRC 2765/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | HDAC4 1584/4885NOS1 1572/4885SRC 3922/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | HDAC4 3952/4885NOS1 4340/4885SRC 1050/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | HDAC4 2351/4885NOS1 659/4885SRC 3462/4885 |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | HDAC4 4418/4885NOS1 4071/4885SRC 1303/4885 |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | CTSE, CTSS, CTSB | HDAC4 1958/4885NOS1 1134/4885SRC 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.